Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia

Chronic L-3,4-dihydroxyphenylalanine (L-dopa) treatment of Parkinson Disease (PD) often leads to debilitating involuntary movements, termed L-dopa-induced dyskinesia (LID). The past few years have seen an unprecedented increase in understanding the neural mechanisms underlying LID manifestation in P...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Parkinsonism & related disorders Jg. 15; S. S64 - S67
Hauptverfasser:	Guigoni, Céline, Bezard, Erwan
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.12.2009
Schlagworte:	Abnormal involuntary movements Animals Dopamine Agents - adverse effects Dopamine Agents - pharmacology Dopamine D1 receptor Dyskinesia, Drug-Induced - etiology Humans L-dopa Levodopa - adverse effects Levodopa - pharmacology Models, Biological Neurology Parkinson's disease Protein Transport - drug effects Receptors, Dopamine D1 - metabolism Sensitisation Signal Transduction - drug effects Signal Transduction - physiology Trafficking AC D3R Parkinson's disease AMPA L-dopa D1R D2R Trafficking LID RGSL DARPP-32 MSN 6-OHDA SNc cAMP Sensitisation AIMs PD GPCR Dopamine D1 receptor MPTP DA Abnormal involuntary movements ERK extracellular signal-regulated kinase cyclic adenosine 3′,5′-monophosphate D1 dopamine receptor G protein-coupled receptors l-3,4-dihydroxyphenylalanine adenylyl cyclase L-dopa-induced dyskinesia regulatory GPCR signalling protein D2 dopamine receptor dopamine and cyclic adenosine 3′,5′-monophosphate-regulated phosphoprotein, 32 kDa substantia nigra pars compacta D3 dopamine receptor 6-hydroxydopamine α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine medium spiny neurons dopamine
ISSN:	1353-8020, 1873-5126, 1873-5126
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!